An Open Label Study of the Effects of Eculizumab in CD59 Deficiency

NCT01579838 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hemolysis

Interventions

DRUG: Eculizumab

Sponsor

Hadassah Medical Organization